Obesity Surgery

, Volume 25, Issue 10, pp 1842–1847 | Cite as

Multicenter Randomized Study of Obesity Treatment with Minimally Invasive Injection of Hyaluronic Acid Versus and Combined with Intragastric Balloon

  • Jerome Dargent
  • François Mion
  • Vianna Costil
  • René Ecochard
  • Frédéric Pontette
  • Valentin Mion
  • Stéphane Angella
Original Contributions



Research into minimally invasive techniques is worthwhile for greater acceptance in bariatric surgery, a useful first step being to evaluate the combination of these with current procedures. We suggest that intragastric balloon (IGB) can be performed with hyaluronic acid (HA) injections at the level of the gastroesophageal junction.


A submucosal restriction is created by circular injection of an absorbable material within a defined area based on endoscopic anatomy. We included 101 patients in a prospective multicenter randomized trial, with average body mass index (BMI) 33.4 (range 27–44), treated from April 2010 to April 2012 by IGB and/or HA injection, sequentially, and followed for two more years. Patients were divided into group 1 (IGB alone), group 2 (IGB followed by HA at IGB removal, at 6 months), and group 3 (HA and IGB at 6 months).


BMI loss at 6 months was inferior in the HA group (32 patients) compared with the IGB groups (68 patients) (2.1 ± 0.4 versus 3.4 ± 0.3, p < 0.05). The efficacy of IGB alone compared with combined treatments (groups 2 and 3) was significantly inferior at 18 months only, but the impact of the treatment sequence (HA before or after IGB) on BMI loss was not statistically significant, although in favor of HA first.


This study did not demonstrate the efficacy of HA injections as an obesity treatment.


Obesity classes I–III Minimally invasive Endoscopy Intragastric balloon Hyaluronic acid injection 


  1. 1.
    Belachew M, Legrand MJ, Vincent V, et al. Laparoscopic adjustable gastric banding. World J Surg. 1998;22:955–63.CrossRefPubMedGoogle Scholar
  2. 2.
    O’Brien PE, McPhail T, Chaston TB, et al. Systematic review of medium-term weight loss after bariatric operations. Obes Surg. 2006;16(8):1032–40.CrossRefPubMedGoogle Scholar
  3. 3.
    Baltasar A, Serra C, Perez N, et al. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg. 2005;15:1124–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Wittgrove AC, Clark GW. Laparoscopic gastric bypass Roux en Y—500 patients: technique and results with 3–60 months follow-up. Obes Surg. 2000;3:233–9.CrossRefGoogle Scholar
  5. 5.
    Dargent J. The patient barrier to growth of bariatric surgery: another French paradox? Obes Surg. 2007;17:287–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Alverdy JC, Prachand V, Flanagan B, et al. Bariatric surgery: a history of empiricism, a future in science. J Gastrointest Surg. 2009;13(3):465–77.CrossRefPubMedGoogle Scholar
  7. 7.
    Busetto L, Dixon J, De Luca M, et al. Bariatric surgery in class I obesity. A position statement from the International Federation for the Surgery and Metabolic Disorders (IFSO). Obes Surg. 2014;24:487–519.CrossRefPubMedGoogle Scholar
  8. 8.
    Weiner R, Gutberlet H, Bockhorn H. Preparation of extremely obese patients for laparoscopic gastric banding by gastric balloon therapy. Obes Surg. 1999;9:261–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15:1161–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Moreno C, Closset J, Dugardeyns S, et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot study. Endoscopy. 2008;40:406–13.CrossRefPubMedGoogle Scholar
  11. 11.
    De Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;9:1354–60.CrossRefGoogle Scholar
  12. 12.
    Pleskow D, Rothstein R, Lo S, et al. Endoscopic full-thickness plication for the treatment of GERD: a multicenter trial. Gastrointest Endosc. 2004;59:163–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Johnson DA, Ganz R, Aisenberg J, et al. Endoscopic implantation of Enteryx for GERD treatment: 12 months results of a prospective multicenter trial. Am J Gastroenterol. 2003;98:1921–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Horgan S, Thompson K, Talamini M, et al. Clinical experience with a multifunctional, flexible surgery system for endolumenal, single-port, and NOTES procedures. Surg Endosc. 2011;25(2):586–92.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    O’Connor KW, Lehman GA. Endoscopic placement of collagen at the lower oesophageal sphincter to inhibit gastroesophageal reflux: a pilot study of 10 medically intractable patients. Gastrointest Endosc. 1988;34:106–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Nocca D, Gagner M, Aggarwal R, et al. Is collagen a good banding material for outlet control of vertical gastroplasty? Preliminary study in pigs. Obes Surg. 2006;16:39–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin A for the treatment of obesity. Obes Surg. 2007;17:732–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Books J, Srivastava ED, Mathus-Vliegen EMH. One year adjustable intragastric balloons: results in 73 consecutive patients in the UK. Obes Surg. 2014;24(5):813–9.CrossRefGoogle Scholar
  19. 19.
    Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20:1496–500.CrossRefPubMedGoogle Scholar
  20. 20.
    Genco A, Maselli R, Frangella F, et al. Effect of consecutive intragastric balloon plus diet vs single BIB plus diet on eating disorders not otherwise specified (EDNOS) in obese patients. Obes Surg. 2013;23:2075–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Mathus-Vliegen EM, de Groot GH. Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity. Obes Surg. 2013;23(5):622–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Marjoux S, Brochard C, Roman S, et al. Botulinum toxin injection for hypercontractile or spastic esophageal motility disorders: may high-resolution manometry help to select cases? Dis Esophagus. 2014. doi:10.1111/dote.12282.PubMedGoogle Scholar
  23. 23.
    Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. Obes Surg. 2008;18:841–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Tai CM, Lin HY, Lien YC, et al. Effectiveness of intragastric balloon treatment for obese patients: one year follow-up after balloon removal. Obes Surg. 2013;23:2068–70.CrossRefPubMedGoogle Scholar
  25. 25.
    Schauer P, Chand B, Brethauer S. The emerging field of endoluminal and transgastric bariatric surgery. Surg Endosc. 2007;21(3):347–56.CrossRefPubMedGoogle Scholar
  26. 26.
    Emerging Technologies and Clinical Issues Committees of the ASMBS. American society for metabolic and bariatric surgery position statement on emerging endosurgical interventions for treatment of obesity. Surg Obes Relat Dis. 2009;5(3):297–98. doi:10.1016/j.soard.2009.02.001.

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Jerome Dargent
    • 1
  • François Mion
    • 2
  • Vianna Costil
    • 3
  • René Ecochard
    • 2
  • Frédéric Pontette
    • 1
  • Valentin Mion
    • 2
  • Stéphane Angella
    • 1
  1. 1.Polyclinique Lyon-NordRillieux-la-PapeFrance
  2. 2.Hôpital E. HerriotLyonFrance
  3. 3.Clinique du TrocadéroParisFrance

Personalised recommendations